Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,756,424
  • Shares Outstanding, K 74,837
  • Annual Sales, $ 76,300 K
  • Annual Income, $ -122,700 K
  • EBIT $ -71 M
  • EBITDA $ -59 M
  • 60-Month Beta 1.30
  • Price/Sales 13.13
  • Price/Cash Flow N/A
  • Price/Book 5.51

Options Overview Details

View History
  • Implied Volatility 99.36% (+14.18%)
  • Historical Volatility 41.41%
  • IV Percentile 50%
  • IV Rank 29.95%
  • IV High 220.79% on 11/14/25
  • IV Low 47.46% on 08/22/25
  • Expected Move (DTE 31) 0.94 (3.92%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 119
  • Volume Avg (30-Day) 369
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 5,655
  • Open Int (30-Day) 10,682
  • Expected Range 22.95 to 24.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.35
  • Number of Estimates 6
  • High Estimate 0.24
  • Low Estimate -0.72
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -12.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.46 +5.88%
on 01/12/26
27.94 -14.89%
on 12/22/25
-3.45 (-12.67%)
since 12/19/25
3-Month
16.00 +48.59%
on 11/07/25
28.49 -16.53%
on 11/26/25
+5.46 (+29.80%)
since 10/20/25
52-Week
9.03 +163.34%
on 04/10/25
28.49 -16.53%
on 11/26/25
+9.90 (+71.33%)
since 01/17/25

Most Recent Stories

More News
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Investment industry veteran Mr. Brian Cherry appointed to Board of Directors Dr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive...

ZYME : 23.95 (+2.05%)
Zymeworks Outlines Strategic Priorities and Outlook for 2026

Positive Phase 3 HERIZON-GEA-01 results for Ziihera ® (zanidatamab-hrii) in first-line HER2-positive (HER2+)  gastroesophageal adenocarcinoma ( GEA) presented at ASCO GI Up to $440.0 million in...

ZYME : 23.95 (+2.05%)
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the...

ZYME : 23.95 (+2.05%)
Zymeworks Announces Participation in Upcoming Conferences

• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera ® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present...

ZYME : 23.95 (+2.05%)
Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline...

ZYME : 23.95 (+2.05%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

AVAI : 0.7350 (-0.69%)
ANVS : 2.83 (-2.08%)
RXRX : 4.53 (-3.00%)
ZYME : 23.95 (+2.05%)
NTLA : 13.13 (+5.04%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...

AVAI : 0.7350 (-0.69%)
ANVS : 2.83 (-2.08%)
RXRX : 4.53 (-3.00%)
ZYME : 23.95 (+2.05%)
NTLA : 13.13 (+5.04%)
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse...

ZYME : 23.95 (+2.05%)
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders Strategic initiative follows positive topline results from pivotal...

ZYME : 23.95 (+2.05%)
Stocks Fall Ahead of Nvidia Earnings and US Economic Data

The S&P 500 Index ($SPX ) (SPY ) on Monday fell by -0.92%, the Dow Jones Industrials Index ($DOWI ) (DIA ) fell by -1.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) fell by -0.83%. December E-mini S&P...

GOOGL : 324.92 (-1.54%)
AAPL : 249.85 (-2.22%)
GLXY : 32.33 (-5.77%)
EXPD : 161.11 (-0.80%)
HPQ : 19.79 (-2.85%)
ALGN : 165.83 (-3.30%)
$IUXX : 25,161.17 (-1.44%)
COIN : 229.29 (-4.92%)
RBRK : 65.88 (-1.82%)
ZNH26 : 111-165 (-0.21%)
ARMK : 39.33 (-0.73%)
TSLA : 425.21 (-2.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 24.56
2nd Resistance Point 24.21
1st Resistance Point 23.84
Last Price 23.95
1st Support Level 23.12
2nd Support Level 22.77
3rd Support Level 22.40

See More

52-Week High 28.49
Last Price 23.95
Fibonacci 61.8% 21.06
Fibonacci 50% 18.76
Fibonacci 38.2% 16.46
52-Week Low 9.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar